22nd Century Group Inc. (NASDAQ: XXII) has appointed James A Mish to its Board. Currently, Mish is the company’s CEO, and the appointment significantly enriches the...
22nd Century Group Inc (NASDAQ: XXII) announced that it is granted Food and Drug Administration (FDA) approval to market and sell its VLN® King and VLN®...
Aurora Cannabis Inc. (NASDAQ: ACB) and 22nd Century Group Inc. (NASDAQ: XXII) have announced a three-way non-exclusive license agreement for licensing biosynthesis intellectual property to Cronos...
22nd Century Group Inc. (NASDAQ: XXII) has announced Q3 2021 financial results and offered its recent business highlights. Net sales increased 6.9% In Q3 2021, net...
Cannabix Technologies Inc. (OTCMKTS: BLOZF) has announced receipt of patent No 17/019728 titled “Apparatus and Methods for Detection of Molecules,” from the US Patent and Trademark...
22nd Century Group Inc (NYSEAMERICAN: XXII), a New York-based biotechnology company, recently released its operational and financial results for the second quarter of 2021. The company...
